 |
160 Products |  |
813 Diseases | | 160 Products |
|
1554 Trials |  |
75234 News |  |
| «12...6263646566676869707172...858859» |
- Nplate (romiplostim) / Amgen, Kyowa Kirin, Doptelet (avatrombopag) / SOBI, Promacta (eltrombopag) / Novartis
PHASE 4 STUDY RESULTS EVALUATING THE SAFETY, EFFICACY, AND TREATMENT SATISFACTION IN CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) AFTER SWITCHING TO AVATROMBOPAG FROM ELTROMBOPAG OR ROMIPLOSTIM () - May 15, 2024 - Abstract #EHA2024EHA_2966;
P4
In a population of patients who weregenerally responding to TPO-RAs prior to a switch to AVA, mean/median PCs were also improved with AVAtreatment, suggesting that patients may experience sustained effectiveness paired with enhanced treatmentsatisfaction when switching from ELT or ROMI. Safety results will be available at the congress.
- CURRENT APPROACHES TO THE TREATMENT OF ACQUIRED AMEGAKARYOCYTIC THROMBOCYTOPENIA: A COMPREHENSIVE REVIEW OF THERAPEUTIC STRATEGIES AND CONSIDERATIONS () - May 15, 2024 - Abstract #EHA2024EHA_2961;
Tocilizumab andAlemtuzumab was used in one patient each with improvement in symptoms. There are multiple heterogeneous treatment options available for AAMT with mixed response rates, but data islacking about the best combination and prioritization of the treatments and randomized prospective trials areneeded to answer these question.
- Nplate (romiplostim) / Amgen, Kyowa Kirin, Promacta (eltrombopag) / Novartis
THROMBOPOIETIN RECEPTOR AGONISTS (TPO-RAS): A PROMISING THERAPY FOR CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA (CIT) () - May 15, 2024 - Abstract #EHA2024EHA_2954;
Furthermore, being able toundergo anticancer therapy without RDI reduction is crucial for both the neoplastic outcome and psychologicalwell-being of the patients. The management of CIT remains an unmet clinical need.
- Promacta (eltrombopag) / Novartis
ELTROMBOPAG INHIBITS THE PROLIFERATION OF CD8 T CELLS THROUGH AN IRON CHELATION MANNER () - May 15, 2024 - Abstract #EHA2024EHA_2950;
Weproposed that eltrombopag may have a dual mechanism of action: inhibiting the proliferation of CD8+ TEMRAcells and inducing G1 cell cycle arrest. This iron chelation-dependent effect suggests a novelimmunomodulatory role for eltrombopag.
- Doptelet (avatrombopag) / SOBI, Tavalisse (fostamatinib) / Rigel
AVATROMBOPAG PLUS FOSTAMATINIB COMBINATION EFFICACY AND SAFETY IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA () - May 15, 2024 - Abstract #EHA2024EHA_2946;
The combination of avatrombopag and fostamatinib has been shown to be effectiveand safe leading to quick response in the majority of treated patients. More research are needed to confirmthese results.
- Tavalisse (fostamatinib) / Rigel
EFFICACY AND SAFETY OF FOSTAMATINIB FOR IMMUNE THROMBOCYTOPENIA IN CLINICAL PRACTICE IN SPAIN: RESULTS OF FOSTAMES, OUR NATIONAL FOSTAMATINIB REGISTRY () - May 15, 2024 - Abstract #EHA2024EHA_2945;
More research are needed to confirmthese results. Themedian number of therapies prior to administration of fostamatinib was 4 (IQR, 2
- Nplate (romiplostim) / Amgen, Kyowa Kirin, Promacta (eltrombopag) / Novartis, Rituxan (rituximab) / Roche
THE PLATELET VARIABILITY INDEX (PVI) SCORE AS A MEASURE OF THE EFFECT OF TREATMENTS FOR IMMUNE THROMBOCYTOPENIA (ITP) () - May 15, 2024 - Abstract #EHA2024EHA_2943;
Splenectomy was associated with the greatest reduction in PVI scores, and TPO receptor agonists wereassociated with the smallest reduction in PVI scores. Along with an increase in platelet count levels, a reductionin PVI scores may be an indicator of the quality of the response to ITP treatments.
- Doptelet (avatrombopag) / SOBI
A EUROPEAN RETROSPECTIVE STUDY TO DESCRIBE REAL-WORLD OUTCOMES, TREATMENT PATTERNS AND RESOURCE USE IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) TREATED WITH AVATROMBOPAG: INTERIM RESULTS () - May 15, 2024 - Abstract #EHA2024EHA_2941;
Along with an increase in platelet count levels, a reductionin PVI scores may be an indicator of the quality of the response to ITP treatments. As of first data cut-off (2 Feb 2024), data relating to 17 patients have been collected: 7 TPO-RA na
- sovleplenib (HMPL-523) / Hutchmed
SOVLEPLENIB IN PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) PTS WITH PRIOR TPO/TPO-RA TREATMENT: SUBGROUP ANALYSIS OF A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY (ESLIM-01) (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_2935;
P3
Sovleplenib significantly and consistently improved platelet counts in primary ITP pts with prior TPO/TPO-RAtreatments, regardless of TPO/TPO-RA treatment types and number of prior regimens. Sovleplenib could be aneffective treatment option for patients with primary ITP.
- Nplate (romiplostim) / Amgen, Kyowa Kirin, Promacta (eltrombopag) / Novartis, Tavalisse (fostamatinib) / Rigel
PROLONGED RESPONSE AFTER TPO-RA DISCONTINUATION IN PRIMARY ITP: LONG TERM FOLLOW-UP OF THE STOPAGO STUDY, A PROSPECTIVE MULTICENTER STUDY (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_2932;
P4
Sovleplenib could be aneffective treatment option for patients with primary ITP. Patients were adults with a persisting or chronic ITP whoachieved a stable complete response (platelet count > 100
- Nplate (romiplostim) / Amgen, Kyowa Kirin, Promacta (eltrombopag) / Novartis
THROMBOPOIETIN-R AGONISTS EFFICACY AND SAFETY IN PREGNANT ITP PATIENTS AND THEIR BABIES: A MULTICENTER RETROSPECTIVE ITP-NET ITALIAN STUDY ON BEHALF OF GIMEMA WORKING GROUP "ANEMIA & THROMBOCYTOPENIA" (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_2929;
In our limited case series treatment with TPO-RA appears safe, manageable and effective in obtainingan optimal plt count for delivery, particularly in patients with chronic, steroid-refractory disease. No thromboticevents nor specific complications for newborns were reported.
- Nplate (romiplostim) / Amgen, Kyowa Kirin
REAL-WORLD EFFECTIVENESS AND SAFETY OF ROMIPLOSTIM IN FRANCE. RESULTS FROM THE PROSPECTIVE, MULTICENTER, NATIONAL CARMEN-FRANCE REGISTRY. (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_2922;
In the French practice, romiplostim is used early in the disease phase. The response rate and the safety profilein the real world confirm data from randomized controlled trials.
- Tavalisse (fostamatinib) / Rigel
REAL-WORLD USE OF FOSTAMATINIB IN FRANCE. RESULTS OF A NATIONAL REGISTRY AT TWO YEARS AFTER MARKETING. (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_2919;
The response rate and the safety profilein the real world confirm data from randomized controlled trials. French authorities recommended the usefostamatinib in case of failure or contraindication to eltrombopag, romiplostim (the two thrombopoietinreceptor agonists
- Nplate (romiplostim) / Amgen, Kyowa Kirin, Promacta (eltrombopag) / Novartis
LONG-TERM RESULTS OF THROMBOPOIETIN RECEPTOR AGONIST WITHDRAWAL IN PRIMARY IMMUNE THROMBOCYTOPENIA RESISTANT TO STANDARD TREATMENT (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_2916;
The possibility of repeated successful TPO-RA withdrawal after restoration of PR was shown. Fig.
- Doptelet (avatrombopag) / SOBI
AVATROMBOPAG IN IMMUNE THROMBOCYTOPENIA (PTI). A REAL-WORLD STUDY OF THE SPANISH ITP GROUP (GEPTI). (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_2915;
AVA can be safely used totreat chronic ITP even where other TPO-RAs have failed. AVA seems to be suitable to treat newly diagnosedand persistent ITP.
- Nplate (romiplostim) / Amgen, Kyowa Kirin, Promacta (eltrombopag) / Novartis, Rituxan (rituximab) / Roche
USE OF CORTICOSTEROID-SPARING TREATMENTS (2ND-LINE AND BEYOND) IN ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA IN EUROPE. A PARALLEL STUDY IN SIX PROSPECTIVE MULTICENTER NATIONAL REGISTRIES (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_2914;
TPO-RAs are the preferred second-line therapy. This ratehas increased over the last decade.
- Doptelet (avatrombopag) / SOBI
REAL-WORLD INSIGHTS INTO AVATROMBOPAG'S EFFECTIVENESS AND SAFETY IN ADULTS WITH IMMUNE THROMBOCYTOPENIA (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_2909;
AVA treatment mayalso help reduce the need for rescue therapy while maintaining a good safety profile. These real-world insightshave important implications for routine clinical practice, supporting the broader use of AVA as an effectiveapproach for treating chronic ITP in adults.
- Tavalisse (fostamatinib) / Rigel
ITALIAN REAL-WORLD EXPERIENCE WITH FOSTAMATINIB IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_2907;
Fosta was used in most cases as fourth or further line of therapy, after failure of TPO-RAs. Our findings indicate that a significant proportion of patients (nearly 40% of the overall population)benefit from fosta after 6 months, suggesting that this treatment may be considered as a manageable andeffective therapeutic option in the real-world practice.
- EFFECT OF NOVEL AGENTS ON THE MECHANISM OF FIBROCYTE-MEDIATED INDUCTION OF MYELOFIBROSIS (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_2712;
In vitro experiments demonstrated that the novel agents examined in this studyeffectively inhibited monocyte differentiation into fibrocytes and reduced certain profibrotic cytokinelevels in the culture supernatant. Further investigation into these mechanisms is anticipated to provideinsights into the antifibrotic mechanisms underlying the action of these novel agents.
- Prolia (denosumab) / Amgen
EFFECT OF DENOSUMAB ON PROGRESSION-FREE SURVIVAL AND BONE HEALTH IN PATIENTS WITH MULTIPLE MYELOMA: A MULTICENTER PROSPECTIVE OBSERVATIONAL STUDY (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_2445;
8%) orosteoporosis (39. 5%), and only 23.
- Prolia (denosumab) / Amgen
CHARACTERIZATION OF BONE MARROW NICHE AND IMMUNOPHENOTYPING IN A MULTIPLE MYELOMA MOUSE MODEL DRIVEN BY COMBINED EXPRESSION OF ACTIVE RANK AND TCL1 (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_2375;
It offers a detailed understanding of the bone marrow niche dynamics,immunosurveillance mechanisms, and genomic alterations, establishing a significant advancement in MMresearch. Our findings not only closely mirror human myeloma, but also unveil potential novel targets fortherapeutic intervention, such as the microenvironment-modulating protein CD39, and allow furtherexploration of the autophagy-linked protein p62, shedding light on its role in drug resistance to proteasomalinhibition.
- HT-6184 / Halia Therap
TRIAL IN PROGRESS: PHASE II STUDY OF THE NLRP3 INFLAMMASOME & MYDDOSOME INHIBITOR HT-6184 IN PATIENTS WITH LOW OR INTERMEDIATE-RISK MYELODYSPLASTIC SYNDROME (MDS) () - May 15, 2024 - Abstract #EHA2024EHA_2304;
This multi-center, Phase IIa clinical trial started enrollment and first patient treatment on 9 December 2023,with the study now active in 8 centers. Preliminary safety, efficacy, and biomarker outcomes data from HT-6184treatment will be presented
- Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
CLINICAL BENEFIT OF LUSPATERCEPT IN TRANSFUSION-DEPENDENT, ERYTHROPOIESIS-STIMULATING AGENT-NAIVE PATIENTS WITH VERY LOW-, LOW- OR INTERMEDIATE-RISK MYELODYSPLASTIC SYNDROMES IN THE COMMANDS TRIAL (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_2281;
P3
Significantly greater proportions of pts treated with luspatercept than with epoetin alfaachieved improvements in Hb levels, reduction in TB and RBC units transfused, and had durable RBC-TIresponses. Luspatercept provided clinically meaningful outcomes, supporting its use as the preferred tx forESA-naive pts with LR-MDS-associated anemia.
- Epogen (epoetin alfa) / Amgen, Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
MULTILINEAGE AND SAFETY RESULTS FROM THE COMMANDS TRIAL IN TRANSFUSION-DEPENDENT, ERYTHROPOIESIS-STIMULATING AGENT-NAIVE PATIENTS WITH VERY LOW-, LOW-, OR INTERMEDIATE-RISK MYELODYSPLASTIC SYNDROMES (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_2276;
P3
A greater proportion of pts treated with luspatercept than with epoetin alfa achieved HI-E. Although only aminority of pts were evaluable for HI-P and HI-N assessments (per the study entry criteria), numerically morepts receiving luspatercept than epoetin alfa achieved HI-P and HI-N responses during wk 1
- Epogen (epoetin alfa) / Amgen, Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
RELATIONSHIP BETWEEN HAEMOGLOBIN AND QUALITY OF LIFE IN TRANSFUSION-DEPENDENT PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROME RECEIVING LUSPATERCEPT OR EPOETIN ALFA (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_2271;
Achieving a Hb level ?10 g/dL was more likely to result in meaningful improvement in anaemia-related fatigueand dyspnoea symptoms as well as QoL on the QLQ-C30. Findings from this analysis will help inform clinicians'decisions on the optimal Hb target for treatment of anaemic TD patients with LR-MDS.
- tapotoclax (AMG 176) / Amgen
A PHASE I STUDY OF THE MYELOID CELL LEUKEMIA 1 (MCL1) INHIBITOR TAPOTOCLAX (AMG 176) IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES AFTER HYPOMETHYLATING AGENT FAILURE (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_2245;
P1
No DLTs were observed, and cardiac AEs self-resolved without dose reductions. Thoughno patients responded, some patients experienced transient blast reduction and decreased RBC transfusionburden.
- Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
LUSPATERCEPT IMPROVES HEMATOPOIESIS IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (MDS): COMPARATIVE BIOMARKER ANALYSIS OF RING SIDEROBLAST-POSITIVE AND -NEGATIVE SUBGROUPS FROM THE PHASE 3 COMMANDS STUDY (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_2211;
P3
The primary responses were favorable to luspatercept and agnostic to RS status bymutational type, VAF cutoff, IPSS-M classification, and longer duration of response. Such improvements werenot observed in ESA-treated pts.
- Epogen (epoetin alfa) / Amgen, Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
COMPARATIVE ANALYSIS OF CLINICAL BENEFIT BY GENOMIC LANDSCAPE AND MUTATIONAL BURDEN OF LUSPATERCEPT VERSUS EPOETIN ALFA IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (MDS) IN THE PHASE 3 COMMANDS STUDY (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_2197;
P3
Luspatercept also showed superior clinical benefit compared with ESA in patientswith common difficult-to-treat mutations and was superior in both SF3B1-mutated and SF3B1-wildtypesubgroups. RSK & SH contributed equally.
- Undisclosed CDK4/6 inhibitor / CS Group, narazaciclib (HX301) / Traws Pharma
THE MULTIKINASE CDK4/6 INHIBITOR NARAZACICLIB OVERCOMES BTK-I RESISTANCE IN MANTLE CELL LYMPHOMA BY TARGETING USP24-P53 SIGNALING AXIS (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_2120;
Our findings demonstrate that narazaciclib is safe and effective as a single agent in preclinical models of MCL,including BTKi-resistant cases. Its combination with ibrutinib achieved a synergistic tumoricidal effect in vitroand in vivo, accelerating cell cycle blockade and, specifically in the BTK-resistant cases, promoting thephosphorylation of USP24, followed by the activation of P53 and the modulation of DNA repair pathway.
- Tecartus (brexucabtagene autoleucel) / Gilead
SUSTAINED COST-EFFECTIVENESS OF BREXUCABTAGENE AUTOLEUCEL FOR THE TREATMENT OF RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA IN PATIENTS AGED 26 YEARS OR OLDER IN ITALY () - May 15, 2024 - Abstract #EHA2024EHA_1855;
BREXU-CEL substantially improves the life-expectancy of patients with R/R B-ALL compared to BLIN, INO, andCHEMO and added life-years are spent in good health. Moreover, BREXU-CEL is cost-effective at list priceversus BLIN and INO and borderline cost-effective versus CHEMO in Italy at a willingness-to-pay threshold of
- Adcetris (brentuximab vedotin) / Takeda, Pfizer
PHASE I-II STUDY COMBINING BRENTUXIMAB VEDOTIN WITH R-DHAP AND AUTOLOGOUS STEM CELL TRANSPLANTATION IN CD30 POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS: RESULTS OF THE HOVON 136 STUDY (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_1406;
BV-R-DHAP is a feasible and effective pre-transplant salvage regimen forCD30+ DLBCL with a CMR of 47% and allows long-term remissions and survival. **
- Venclexta (venetoclax) / Roche, AbbVie
FLAG-IDA + VENETOCLAX (VEN) IN NEWLY DIAGNOSED (ND) OR RELAPSED / REFRACTORY (RR) AML (Hall Dali 1) - May 15, 2024 - Abstract #EHA2024EHA_1343;
** Induction comprised fludarabine 30mg/m2 D2
- Ibrance (palbociclib) / Pfizer, Verzenio (abemaciclib) / Eli Lilly
INHIBITION OF CDK4/6 AUGMENTS ATRA-INDUCED DIFFERENTIATION ACROSS ACUTE MYELOID LEUKAEMIA SUBTYPES () - May 15, 2024 - Abstract #EHA2024EHA_1065;
Additionally, we observed that ATRA-induced differentiation isenhanced when in combination with CDK4/6 inhibitors across a wide range of AML subtypes. Although theseresults should be validated in additional AML models, they show that a primary mechanism of action ofCDK4/6 inhibitors is cell cycle arrest accompanied by the induction of differentiation, and that, in combinationwith ATRA, this effect can be augmented.
- Ibrance (palbociclib) / Pfizer
DUAL TARGETING OF FLT3-ITD AND CLK BY SCREENED DONATED CHEMICAL PROBES IN ACUTE MYELOID LEUKEMIA (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_1039;
The unexpected discovery of potent FLT3 signalinginhibition specifically in FLT3-ITD mutated AML cases introduces a dual-targeting approach that couldsignificantly improve AML treatment. This finding not only highlights the utility of DCPs in therapeutic discoverybut also paves the way for innovative, more effective AML treatment protocols.
- obecabtagene autoleucel (AUTO1) / Autolus
OBECABTAGENE AUTOLEUCEL IN ADULT RELAPSED/REFRACTORY B CELL ACUTE LYMPHOBLASTIC LEUKEMIA: SURVIVAL AND POTENTIAL IMPACT OF CAR-T CELL PERSISTENCE AND STEM CELL TRANSPLANTATION IN THE FELIX STUDY (Hall N104) - May 15, 2024 - Abstract #EHA2024EHA_914;
P1/2
This finding not only highlights the utility of DCPs in therapeutic discoverybut also paves the way for innovative, more effective AML treatment protocols. Patients received bridging therapy as appropriate and underwent lymphodepletion ( fludarabine, 4
- Blincyto (blinatumomab) / Astellas, Amgen
USE OF BLINATUMOMAB AS BRIDGE THERAPY BEFORE ALLOGENEIC BONE MARROW TRANSPLANTATION IN PATIENTS WITH ACUTE B-LYMPHOBLASTIC LEUKEMIA (B-ALL) () - May 15, 2024 - Abstract #EHA2024EHA_910;
Despite the limited patient cohort, our analysis demonstrated the efficacy of blinatumomab as bridge therapyin patients with MRD, previously received treatment, as well as in patients with relapsed B-ALL. An analysis of the use of blinatumomab revealed that the drug's tolerability was satisfactory, and the therapy'stoxicity was manageable, thereby enabling further allo-HSCT.
- Blincyto (blinatumomab) / Astellas, Amgen
A COMBINED TYROSINE KINASE INHIBITOR AND BLINATUMOMAB APPROACH IN PHILADELPHIA CHROMOSOME-POSITIVE OR PHILADELPHIA CHROMOSOME-LIKE ACUTE LYMPHOBLASTIC LEUKEMIA () - May 15, 2024 - Abstract #EHA2024EHA_903;
An analysis of the use of blinatumomab revealed that the drug's tolerability was satisfactory, and the therapy'stoxicity was manageable, thereby enabling further allo-HSCT. Blinatumomab+TKIs offer a safe and effective front-line treatment option for Ph+ ALL.
- Blincyto (blinatumomab) / Astellas, Amgen
EFFICACY AND SAFETY OF BLINATUMOMAB BRIDGING THERAPY AFTER INDUCTION FOR NEWLY DIAGNOSED PEDIATRIC B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA () - May 15, 2024 - Abstract #EHA2024EHA_899;
In newly diagnosed pediatric B-ALL pts, Blin as a bridging therapy after induction is aneffective regimen, resulting in deep remission, and low-grade treatment-related AEs. These promising findingsprovide rationale for integrating Blin into frontline therapy recommendations.
- Blincyto (blinatumomab) / Astellas, Amgen, Nailike (olverembatinib) / Ascentage Pharma, Takeda
A PRELIMINARY STUDY ON THE SAFETY AND EFFICACY OF LOW-DOSE ORLOTINIB COMBINED WITH CHEMOTHERAPY IN NEWLY DIAGNOSED PH+ ACUTE B-CELL LYMPHOBLASTIC LEUKEMIA () - May 15, 2024 - Abstract #EHA2024EHA_895;
Low-dose orlotinib combined with conventional chemotherapy for newly diagnosedPh(+)-B-ALL can achieve good remission, including deep remission. This treatment approach may allow amajority of patients with newly diagnosed Ph(+) B-ALL to achieve long-term disease-free survival withoutundergoing hematopoietic stem cell transplantation.
- Blincyto (blinatumomab) / Astellas, Amgen
BLINATUMOMAB EXPERIENCE IN PEDIATRIC ALL TREATMENT: IS IT EFFECTIVE IN EXTRAMEDULLARY DISEASE? () - May 15, 2024 - Abstract #EHA2024EHA_893;
Blinatumomab shows significant benefits in terms of treatment response and low side effect profile in patientswith relapsed/refractory ALL. Blinatumomab should be considered an effective and safe treatment alternativefor EM disease
- Blincyto (blinatumomab) / Astellas, Amgen
MULTIPLE SHORT-COURSE TREATMENT OF BLINATUMOMAB CONSOLIDATION THERAPY REDUCES CUMULATIVE RELAPSE RATE IN B-ALL PATIENTS WITH DAY 19 BONE MARROW MRD ? 1.0*10-2 UNDER CCCG-ALL 2020 PROTOCOL () - May 15, 2024 - Abstract #EHA2024EHA_889;
The application of multiple short-course blinatumomab consolidation therapy demonstrated a potential trendin mitigating the risk of CRR among intermediate-risk pediatric B-ALL patients with poor early chemotherapyresponse. However, more clinical research and data are required to confirm these findings.
- Blincyto (blinatumomab) / Astellas, Amgen
EFFICACY AND SAFETY OF BLINATUMOMAB IN ADULT PATIENTS WITH B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: A REAL-WORLD STUDY () - May 15, 2024 - Abstract #EHA2024EHA_887;
However, more clinical research and data are required to confirm these findings. Treatment with blinatumomab is effective in the treatment of R/R B-ALL with acceptable safety profilecomparable to the published literature.
- Blincyto (blinatumomab) / Astellas, Amgen
SAFETY AND EFFICACY OF MULTIPLE SHORT-COURSE BLINATUMOMAB FOR RELAPSED CD19-POSITIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION () - May 15, 2024 - Abstract #EHA2024EHA_886;
The response rate to short-course blinatumomab treatment for R-B-ALL after allo-HCT is effective, coupledwith no incidence of serious adverse events grade 1-4 acute or chronic GVHD. Considering the small samplesize, limited amount of data and short follow-up, the current conclusion still requires strong evidence fromlarge size clinical trials.
- Blincyto (blinatumomab) / Astellas, Amgen
OUTCOMES OF SEQUENTIAL ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION AFTER BLINATUMOMAB IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS WITH LOW OR UNDETECTABLE MINIMAL RESIDUAL DISEASE () - May 15, 2024 - Abstract #EHA2024EHA_884;
Post-transplantation acute graft-versus-host-disease(GVHD) prophylaxis consisted of cyclophosphamide and cyclosporine. Although this study is limited by its design and small size, our data support the use of pre-transplantblinatumomab treatment in adult patients who achieved MRD response in first remission.
- Blincyto (blinatumomab) / Astellas, Amgen
EFFICIENCY OF MULTI-COURSE BLINATUMOMAB COMBINED WITH REDUCED-DOSE CHEMOTHERAPY IN CHEMO INTOLERANT MEDIUM TO HIGH-RISK PEDIATRIC B-ALL PATIENTS WITH SYSTEMIC FUNGAL DISEASE () - May 15, 2024 - Abstract #EHA2024EHA_883;
This is the first report of pediatric patients with B-ALL completing nine courses ofblinatumomab, maintaining MRD-negative remission statues, hypogammaglobulinemia sustaining for morethan one year after completing all the therapy and necessitating replacement therapy with no irreversible sideeffects. Our findings highlight the effectiveness and safety of multi-course blinatumomab combined withreduced dose chemotherapy in two pediatric patients with B-ALL.
- Blincyto (blinatumomab) / Astellas, Amgen
CLINICAL OBSERVATIONS OF BLINATUMOMAB IN THE TREATMENT OF CHILDREN WITH B-CELL PRECURSOR ACUTE LYMPHOCYTIC LEUKEMIA () - May 15, 2024 - Abstract #EHA2024EHA_882;
For MRD-positive pts, 1 treatment course of blinatumomab resulted in a high rate of MRD conversion. Inpts with R/R B-ALL, treatment with blinatumomab followed by allo-HSCT exhibited a high OS.
- Rituxan (rituximab) / Roche
RITUXIMAB AS A SALVAGE TREATMENT FOR MINIMAL RESIDUAL DISEASE (MRD) RELAPSE IN PHILADELPHIA NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA EXPRESSING CD 20 ANTIGEN () - May 15, 2024 - Abstract #EHA2024EHA_879;
Nevertheless, itspotential as a single agent to eradicate MRD in the setting of relapse has not been extensively investigated inthis subset of patients for. The described case represents a proof of concept for rituximab's efficacy as a single-agent salvage therapy in a heavily pre-treated patient, including blinatumomab, with multiple comorbiditieswho experienced multiple MRD relapses.
- Blincyto (blinatumomab) / Astellas, Amgen, Nailike (olverembatinib) / Ascentage Pharma, Takeda
COMBINATION OF THIRD GENERATION TKI OLVEREMBATINIB AND CHEMOTHERAPY OR BLINATUMOMAB FOR NEW DIAGNOSED ADULT PH+ ALL PATIENTS (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_873;
Among the 31 patients enrolled, a notable rate of 1-years survival and CMR was observed, whichholds promise for improved long-term survival. Both the TKI+chemotherapy and TKI+BITE groups showedgood clinical outcomes, although the TKI+BITE group had the potency of better survival thanTKI+chemotherapy group.
- Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
TARGETED- AND IMMUNO-BASED THERAPIES FOR ADULTS WITH TP53-MUTATED ACUTE LYMPHOBLASTIC LEUKEMIA (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_871;
Our results show that novel therapies are effective in ALL withTP53 mutations, leading to high remission rates and MRD- responses. Previous exposure to novel therapies didnot seem to impact response to subsequent novel therapies.
- Blincyto (blinatumomab) / Astellas, Amgen
REAL-WORLD UTILIZATION OF BLINATUMOMAB IN ADULT AND PEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA IN FRANCE: RESULTS FROM THE ATHENA STUDY (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_870;
The present study allows a nationwide assessment of the blinatumomab-based strategies for the treatment ofadults and children with ALL. Whereas blinatumomab may be given as a bridge to HSCT, especially in children,this analysis reveals that a significant proportion of patients received repeated cycles of blinatumomab withoutHSCT.